Home » Newsletters » BioWorld Science

BioWorld Science

March 15, 2002

View Archived Issues

Orally active acetylcholinesterase and 5-HT uptake inhibitor proposed for Alzheimer's disease

Protopic cleared for launch in Europe

GK-04489, a new compound with efficacy in arterial thrombosis and cerebral ischemia

Findings presented at AAAAI meeting further support development of Genaera's mucoregulator

BIA-2-024, a new antiepileptic drug, evaluated for metabolism in animals and in vitro

NeoTherapeutics develops promising new family of antipsychotic drugs

Potent and selective integrin inhibitors synthesized at Celltech

First phase I trial of anti-HIV-1 human MAbs assessing safety and pharmacokinetics

ICAgen research leads to two new series of antiarrhythmic agents

GSK describes novel fatty acid synthase FabH inhibitors for bacterial infections

Signal discloses a novel group of JNK inhibitors for a wide range of conditions

More thrombin inhibitors in development at Merck

Antitumor activity of AN-238 against human colorectal cancers independent of p53 status

ISIS-104838 enters second phase II trial in RA

Collateral Therapeutics gains rights to EPAS1 gene

Phase I results show Product R to be safe and well tolerated

Cambrex to manufacture Bioheart's MyoCell therapy

IL-9 blockade continues to show promise for the treatment of asthma

Extended-release Zerit has similar virological activity to immediate-release drug

Risperdal approved for delaying schizophrenia relapse in U.S.

Trisenox approved in Europe for acute promyelocytic leukemia

Keryx initiates phase II dosing of KRX-101 in HIV-associated nephropathy

Third of three phase III trials under way for AC-2993 in treatment of type 2 diabetes

Bavarian Nordic reviews 2001 progress, 2002 outlook

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 29, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...